MNGI-12. A RETROSPECTIVE INTERVENTIONAL COHORT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SANDOSTATIN LAR (OCTREOTIDE ACETATE) FOR THE TREATMENT OF MENINGIOMAS IN ADULT PATIENTS
Meningioma is the most common primary intracranial tumor in adults. Thorough majority of tumors are slow growing, many patients fail first-line treatments with surgery and/or radiation. Others are poor surgical candidates for definitive surgical resection due to their age, tumor location or associat...
Saved in:
Published in | Neuro-oncology (Charlottesville, Va.) Vol. 19; no. suppl_6; p. vi134 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
06.11.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Meningioma is the most common primary intracranial tumor in adults. Thorough majority of tumors are slow growing, many patients fail first-line treatments with surgery and/or radiation. Others are poor surgical candidates for definitive surgical resection due to their age, tumor location or associated medical comorbidities. Few targeted therapies and biologics for meningioma are studied, and they have limited efficacy. This study aims to assess the efficacy and safety of Sandostatin LAR as a potential treatment for recurrent, treatment resistant meningiomas. The retrospective chart review included patients over 18 years of age and diagnosed with meningioma who were administered Sandostatin LAR from 01/01/2010 until 06/01/2017 at the University of California, Irvine (UCI). The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoint was assessing safety. There were 47 patients included in the chart review. The mean age was 64 years old and 69.6% were female. The mean KPS score was 80 (60-100). The majority of patients were diagnosed with WHO grade 1 meningioma (73.3%) compared to WHO grade 2 (11.1%) and WHO grade 3 (15.6%). Of the 47 patients, 14 experienced disease progression and 6 died. The mean overall survival times for grade 1, 2, and 3 were 4.5, 2.3, and 0.91 years respectively. Median time to progression for grade 1, 2, and 3 were 3.1, 2.3, and 0.20 years respectively. The most common AE was diarrhea which occurred in 19 out of 47 patients. Overall, Sandostatin LAR was well tolerated. This is the largest reported cohort of meningioma patients treated with Sandostatin LAR and it suggests that Sandostatin LAR can be an effective, well tolerated treatment for these patients. |
---|---|
AbstractList | Meningioma is the most common primary intracranial tumor in adults. Thorough majority of tumors are slow growing, many patients fail first-line treatments with surgery and/or radiation. Others are poor surgical candidates for definitive surgical resection due to their age, tumor location or associated medical comorbidities. Few targeted therapies and biologics for meningioma are studied, and they have limited efficacy. This study aims to assess the efficacy and safety of Sandostatin LAR as a potential treatment for recurrent, treatment resistant meningiomas. The retrospective chart review included patients over 18 years of age and diagnosed with meningioma who were administered Sandostatin LAR from 01/01/2010 until 06/01/2017 at the University of California, Irvine (UCI). The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoint was assessing safety. There were 47 patients included in the chart review. The mean age was 64 years old and 69.6% were female. The mean KPS score was 80 (60-100). The majority of patients were diagnosed with WHO grade 1 meningioma (73.3%) compared to WHO grade 2 (11.1%) and WHO grade 3 (15.6%). Of the 47 patients, 14 experienced disease progression and 6 died. The mean overall survival times for grade 1, 2, and 3 were 4.5, 2.3, and 0.91 years respectively. Median time to progression for grade 1, 2, and 3 were 3.1, 2.3, and 0.20 years respectively. The most common AE was diarrhea which occurred in 19 out of 47 patients. Overall, Sandostatin LAR was well tolerated. This is the largest reported cohort of meningioma patients treated with Sandostatin LAR and it suggests that Sandostatin LAR can be an effective, well tolerated treatment for these patients. |
Author | Dandekar, Manisha Billimek, John Cadena, Gilbert Kong, Xiao-Tang Bota, Daniela Nguyen, Emely Fu, Beverly Carrillo, Jose Hsu, Frank PK |
AuthorAffiliation | 3 UC Irvine Medical Center , Orange, CA , USA 1 Chao Family Comprehensive Brain Tumor Program Clinic , Orange, CA , USA 2 University of California , Irvine, Irvine, CA , USA 5 Chao Family Comprehensive Cancer Center Brain Tumor Program , Orange, CA , USA 4 UCI Medical Center , Orange, CA , USA |
AuthorAffiliation_xml | – name: 5 Chao Family Comprehensive Cancer Center Brain Tumor Program , Orange, CA , USA – name: 2 University of California , Irvine, Irvine, CA , USA – name: 1 Chao Family Comprehensive Brain Tumor Program Clinic , Orange, CA , USA – name: 4 UCI Medical Center , Orange, CA , USA – name: 3 UC Irvine Medical Center , Orange, CA , USA |
Author_xml | – sequence: 1 givenname: Emely surname: Nguyen fullname: Nguyen, Emely – sequence: 2 givenname: Beverly surname: Fu fullname: Fu, Beverly – sequence: 3 givenname: Manisha surname: Dandekar fullname: Dandekar, Manisha – sequence: 4 givenname: Jose surname: Carrillo fullname: Carrillo, Jose – sequence: 5 givenname: Xiao-Tang surname: Kong fullname: Kong, Xiao-Tang – sequence: 6 givenname: Gilbert surname: Cadena fullname: Cadena, Gilbert – sequence: 7 givenname: Frank PK surname: Hsu fullname: Hsu, Frank PK – sequence: 8 givenname: John surname: Billimek fullname: Billimek, John – sequence: 9 givenname: Daniela surname: Bota fullname: Bota, Daniela |
BookMark | eNpVkc9q3DAQxkVJoUnaB-htjunBG_2xZPtSELacNXitYGkDexLetTbdktjBTkL6Nn2GPkKfrEq2FHoYZuBjfvMN3xk6GcbBI_SZ4AXBGbsc_NM47C6H8YWIdME5fodOCacs4qkQJ28zjVJOkg_obJ6_Y0wJF-QU_Vo1V1VE6ALk75-tsq021yq31Y2CqrGqvVGNrXQja8j1UrcWjF0XG7AapDHKGLBLBaosq1zmG5BNAUaWym5Al2FqCm2stFUDtWzhQue2VdpWhQKZqyCoL1Dq9o0RFGlX4drrZuhV8KVX0gQbIIt1beE6gIJuPqL3--5u9p_-9nO0DhfzZVTrq2CjjnYkTXGU0CzGCaMZ8-FXHndbwvFWpElMtwnDe57thaC-x6L3SUf7Pk5YqMT3Me0JZ-wcfT1yH562977f-eFx6u7cw3S476YfbuwO7n9lOHxzt-Oz4yKjKU4DgBwBu2mc58nv_-0S7F5Tc8fU3DE1F1JjfwDF5oN8 |
CitedBy_id | crossref_primary_10_1007_s11912_020_00937_4 crossref_primary_10_3389_fneur_2020_00373 |
ContentType | Journal Article |
Copyright | The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2017 |
Copyright_xml | – notice: The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2017 |
DBID | AAYXX CITATION 5PM |
DOI | 10.1093/neuonc/nox168.550 |
DatabaseName | CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1523-5866 |
EndPage | vi134 |
ExternalDocumentID | 10_1093_neuonc_nox168_550 |
GroupedDBID | --- .2P .I3 .XZ .ZR 0R~ 123 18M 1TH 2WC 36B 4.4 48X 53G 5VS 5WD 70D AABZA AACZT AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAYXX ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQNK ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CITATION CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMB EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HYE HZ~ IOX J21 KBUDW KOP KQ8 KSI KSN MHKGH N9A NGC NOMLY NOYVH O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM Q1. Q5Y RD5 RHF ROX RPM RUSNO RW1 RXO SV3 TEORI TJX TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ~91 5PM |
ID | FETCH-LOGICAL-c1880-7294073293e21554ab150b68742b730f59f662ed06de7a2dd473d477ed42d1533 |
IEDL.DBID | RPM |
ISSN | 1522-8517 |
IngestDate | Tue Sep 17 21:25:08 EDT 2024 Fri Aug 23 01:51:58 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | suppl_6 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1880-7294073293e21554ab150b68742b730f59f662ed06de7a2dd473d477ed42d1533 |
OpenAccessLink | https://academic.oup.com/neuro-oncology/article-pdf/19/suppl_6/vi134/21592705/nox168.550.pdf |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5692808 crossref_primary_10_1093_neuonc_nox168_550 |
PublicationCentury | 2000 |
PublicationDate | 2017-11-06 |
PublicationDateYYYYMMDD | 2017-11-06 |
PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-06 day: 06 |
PublicationDecade | 2010 |
PublicationPlace | US |
PublicationPlace_xml | – name: US |
PublicationTitle | Neuro-oncology (Charlottesville, Va.) |
PublicationYear | 2017 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
SSID | ssj0021561 |
Score | 2.2371504 |
Snippet | Meningioma is the most common primary intracranial tumor in adults. Thorough majority of tumors are slow growing, many patients fail first-line treatments with... |
SourceID | pubmedcentral crossref |
SourceType | Open Access Repository Aggregation Database |
StartPage | vi134 |
SubjectTerms | Abstracts |
Title | MNGI-12. A RETROSPECTIVE INTERVENTIONAL COHORT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SANDOSTATIN LAR (OCTREOTIDE ACETATE) FOR THE TREATMENT OF MENINGIOMAS IN ADULT PATIENTS |
URI | https://pubmed.ncbi.nlm.nih.gov/PMC5692808 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3datswFBZNL8Zuxrof1q0t52IX2yBxY9lycikcpfGorWArJbkylq3QwuqU0sIeZ8_QR-iT7cg_o7ndhbHhIFn4iHO-zzr6RMhXvWWmZGw7tOJgSFAoxkEkcPhkxtqjWpeu3TscJ2yx8n6u_fUB8fu9ME3RfqlvRvWv21F9c93UVt7dlk5fJ-Ys49BnU3dyPnEGZBBQ2lP0jmUhIWlFUpFl2YPn-6XMKXVq87irS6fe_R6zyci3e-1fJKP9osgXWWb-lrzp4CHwdhhH5MDU78iruFsAf0-e4uQiGo7dEfDnP6lQqcyWIlTRlYBG3PZKJK26LYRyIVMFFvFtQEngmY2coBYCEJtGIQ83wJMZZHwu1AbkHJ-SmcwUV1EClzyFbzJUqZAqmgngoUCD-A5IGps-0MKVPQjAtsR7hOOSMc9wGMBnq0sFS-wI7dkHssI3hIthd-zCsLTibPZwW2R5FHGAcS3aKDSCRs0mSKI1xoOtP90y5prqnFUmKNyq8gKKV2Aqz60sfPxIDutdbT4RMK6hrDBVVSDrqzAVMub5pvQD42MULopj8qP__vldq66Rt6viNG-dlbfOytFZxyTY89C_FlYhe9-CE6dRyu4myuf_bvmFvHZtHrf_kdkJOXy4fzSniEIe9BkZXKzHZ83c-ws-q9RW |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLWGQQI2vEcMz7tgAUhNpk7itEsrdUmgSarGraarKE5cMYJJR6iVEF_DN_AJfBnXeaApO1hEsXRlx5Gd63Pi63MJea02TJeMbQZGHAwJioN-EAkclvRQuY5SJTVnh-OEhUv3w7l3fkS8_ixME7Rfqgur_nJp1RefmtjKq8vS7uPE7HkceGxMR2cj-wa5id8r9XqS3vEspCStTCryLJN6vt_MHDt2rffburTr7bchG1meOW1_bTk6DIu8ts5M75FV38M2vOSztd8pq_z-l3jjP7_CfXK3Q57AW_MDcqTrh-RW3O2tPyI_4-R9NBhSC_ivHwshF2k2F4GMVgIa3dyVSFrhXAjSMF1IMGByDTIFnhmnDDIUgLA3CniwBp5MIONTIdeQTrGUTNJMchklMOMLeJMGciFSGU0E8ECgQbwF5KNNG2jh0uQYMDXxHmG_0phn2A3gk-VMwhwbQnv2mCzxCUE46DI6DEqj-2by5iKBdBBiaGqATKEQjyo2Qn6u0NVsvPGGMaqrM1Zpv6BV5foOXr6uXFoZZHpCjuttrZ8Q0FQ7rNBVVSChrHCVZcz1dOn52kMHXxSn5F0_sPlVK9yRtxvuTt7OgrydBTnOglPiHwz9nxpGfPvQggPaiHB3A_j0v2u-IrdDGc_yWZR8fEbuUAMXzO9q9pwc777u9QsEOzv1spnavwHpYPVh |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjpswFLXaqTTqpu-qM3150UVbKTAxYJKlBU5DGyACZzSZDcLYqKPOkKhKpKpf02_oJ_TLeg2hSrqcBcLSxWB0jX0Ovj4XoXeyprqitB4YcTAgKA6Mg0DgoKSH0nWkrIjZOxwndLpwP194F3upvtqg_UpeWc31jdVcfW1jK9c3ld3HidnzOPDomIzORvZa1fZddA--WeL3RH3HtYCWdFKpwLVM-vl-QXPs2I3erprKblY_hnRkeWbH_d6UdBgauTfXTB6iy76VXYjJN2u7kVb18z8Bx1u9xiP0YIdAMesueYzu6OYJOo53a-xP0e84-RQNhsTC7M-vjIsszec8ENE5x61-7jlPOgFdHKTTNBPYgMolFilmuRmcsZhyDPA3CliwxCwJcc4mXCxxOoFSEqa5YCJK8Ixl-H0aiIynIgo5ZgEHA_-AgZe29wALEybXgKkJ5wjalcYsh2ZgFi5mAs_hRmDPn6EFPCGYDnaZHQaV0X8z-XOBSDoANTQxgKaUgEslHQFPlzDk1N64ppRodUaV9kuilOs7cPhauUQZhPocHTWrRr9AWBPt0FIrVQKxVDDbUup6uvJ87cFAX5Yn6GPv3GLdCXgU3cK7U3Q9oeh6QgE94QT5B-7_V8OIcB9awKmtGPfOiae3rvkWHc_DSTGLki8v0X1iUIP5a01foaPN961-DZhnI9-0vfsvB3n34Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MNGI-12.+A%C2%A0RETROSPECTIVE+INTERVENTIONAL+COHORT+STUDY+TO+ASSESS+THE+EFFICACY+AND+SAFETY+OF+SANDOSTATIN+LAR+%28OCTREOTIDE+ACETATE%29+FOR+THE+TREATMENT+OF+MENINGIOMAS+IN+ADULT+PATIENTS&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Nguyen%2C+Emely&rft.au=Fu%2C+Beverly&rft.au=Dandekar%2C+Manisha&rft.au=Carrillo%2C+Jose&rft.date=2017-11-06&rft.issn=1522-8517&rft.eissn=1523-5866&rft.volume=19&rft.issue=suppl_6&rft.spage=vi134&rft.epage=vi134&rft_id=info:doi/10.1093%2Fneuonc%2Fnox168.550&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_neuonc_nox168_550 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon |